CAR T Company Advances to Phase III Trial

Genetic Engineering and Biotechnology News · health

Caribou Biosciences is preparing to advance its allogeneic CAR T-cell therapy to a pivotal Phase III clinical trial. This move follows successful genome editing strategies and product optimization, including the selection of donors under 30 years old. The company aims to widen patient access to this innovative treatment.